Anatara Lifesciences Ltd AI Stock Analysis
Want to see AU:ANR full AI Analyst Report?
Anatara Lifesciences Ltd (ANR) AI Stock Analysis
Anatara Lifesciences Ltd
(ASX:ANR)
The overall score is driven primarily by very weak financial fundamentals—no durable revenue, ongoing losses, eroding equity, and consistently negative cash flows—indicating a high-risk profile. Technical indicators point to a depressed, oversold share price without convincing positive momentum, while valuation metrics, including a negative P/E and absence of dividends, provide limited support and reinforce the speculative nature of the stock.
Anatara Lifesciences Ltd (ANR) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 2.53M
- Dividend Yield
- ―
- Average Volume (3M)
- 500.98K
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 1.05
- Revenue Growth
- ―
- EPS Growth
- 64.58%
- Country
- Australia
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Anatara Lifesciences Ltd Business Overview & Revenue Model
Company Description
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointe...
How the Company Makes Money
null
Anatara Lifesciences Ltd Financial Statement Overview
Summary
Financial performance is very weak, with no sustained revenue, persistent deep losses, and declining assets and equity, partly offset by the absence of debt and a recent reduction in cash burn.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
25Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 140.84K | 0 | 969.46K | 644.03K | 0 | 0 |
| Gross Profit | 24.31K | -84 | -633.97K | -748.91K | -24.76K | -24.68K |
| EBITDA | -1.25M | -1.25M | -1.96M | -1.46M | -3.21M | -2.97M |
| Net Income | -933.23K | -933.23K | -1.95M | -1.45M | -2.02M | -2.53M |
Balance Sheet | ||||||
| Total Assets | 820.39K | 820.39K | 1.15M | 1.67M | 1.42M | 1.77M |
| Cash, Cash Equivalents and Short-Term Investments | 470.92K | 470.92K | 101.36K | 982.11K | 401.18K | 1.17M |
| Total Debt | 0 | 0 | 407.42K | 0 | 0 | 65.80K |
| Total Liabilities | 108.86K | 108.86K | 612.42K | 306.85K | 494.83K | 403.35K |
| Stockholders Equity | 711.54K | 711.54K | 535.97K | 1.36M | 924.54K | 1.36M |
Cash Flow | ||||||
| Free Cash Flow | -339.24K | -339.24K | -2.27M | -1.25M | -2.26M | -2.24M |
| Operating Cash Flow | -339.24K | -339.24K | -2.27M | -1.25M | -2.26M | -2.23M |
| Investing Cash Flow | 0 | 0 | 0 | 50.00K | -1,726 | -56.56K |
| Financing Cash Flow | 708.80K | 708.80K | 1.39M | 1.83M | 1.49M | -22.44K |
Anatara Lifesciences Ltd Peers Comparison
Overall Rating
AU:BIO63Neutral
AU:RCE46Neutral
AU:IMC45Neutral
AU:ANR42Neutral
AU:EZZ42Neutral
AU:BOT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | AUD 79.84M | 20.19 | 46.74% | ― | 29.68% | 1520.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | AUD 114.72M | -7.33 | 84.67% | ― | ― | 42.51% | |
| 45Neutral | AUD 11.95M | -2.87 | -31.88% | ― | 5.85% | 45.13% | |
| 42Neutral | AUD 2.53M | -2.35 | -101.34% | ― | ― | 64.58% | |
| 42Neutral | AUD 13.64M | -2.56 | -20.36% | 13.76% | -30.79% | -177.68% | |
| 38Underperform | AUD 27.63M | -0.28 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:ANR | Anatara Lifesciences Ltd | 0.01 | 0.00 | 0.00% | |
| AU:IMC | Immuron Limited | 0.04 | -0.03 | -41.27% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.11 | -91.67% | |
| AU:EZZ | EZZ Life Science Holdings Ltd. | 0.29 | -2.09 | -87.82% | |
| AU:BIO | Biome Australia Ltd | 0.34 | -0.07 | -15.85% | |
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.38 | -0.05 | -11.76% |
Anatara Lifesciences Ltd Corporate Events
Anatara Lifesciences Narrows Annual Loss but Faces Going-Concern Warning
Anatara Lifesciences Ltd is a biotechnology company focused on developing therapeutic products, with its activities reflected through consolidated financial reporting for the group. The company operates without paying dividends, indicating an emphasi...
Anatara Advances Anti-Obesity Candidate AOC and GaRP IBS Program Amid Strategic Review
Anatara Lifesciences reported Q4 FY26 progress on its Anti-Obesity Project, where pre-clinical studies identified a candidate compound, AOC, showing statistically significant effects in attenuating post-semaglutide weight regain and reducing visceral...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026
